NCT06473948

To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects

A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect of JMKX001899 on the QTc Interval in Healthy Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 27 (estimated)
• Sponsor: Jemincare · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study to assess the effect of JMKX001899 on QTc interval in healthy volunteers

Detailed description

A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of JMKX001899 Administered as a Tablet Formulation Under Fed Conditions in Healthy Subjects

Conditions

• Solid Tumor, Adult

Interventions

Type	Name	Description
DRUG	JMKX001899	Participants will receive JMKX001899 500mg tablet, orally once on Day 1
DRUG	JMKX001899	Participants will receive JMKX001899 750mg tablet, orally once on Day 1
DRUG	JMKX001899	Participants will receive JMKX001899 1000mg tablet, orally once on Day 1
DRUG	Placebo	Participants will receive JMKX001899 matching placebo, tablet, orally once on Day 1

Timeline

• Start date: 2024-07-10
• Primary completion: 2024-09-24
• Completion: 2025-02-27
• First posted: 2024-06-25
• Last updated: 2024-06-25